Related Experiment Videos
Thrombocytopenia associated with moxalactam administration
Drug Intelligence & Clinical Pharmacy
|February 1, 1984
Summary
Moxalactam disodium administration led to severe thrombocytopenia (low platelet count) in an elderly patient, despite vitamin K therapy. This case highlights the critical risk of hemorrhage associated with this antibiotic.
Area of Science:
- Pharmacology
- Hematology
- Clinical Medicine
Background:
- Moxalactam disodium is a broad-spectrum antibiotic.
- Thrombocytopenia is a known potential adverse effect of certain antibiotics.
Observation:
- An 84-year-old male patient developed thrombocytopenia during moxalactam disodium administration.
- The patient exhibited decreased platelet count, prolonged clotting times, and signs of hemorrhage including petechiae and ecchymoses.
Findings:
- Discontinuation of moxalactam and initiation of vitamin K therapy did not reverse the thrombocytopenia or improve the patient's condition.
- The patient's platelet count decreased further during vitamin K therapy, and he ultimately expired.
Implications:
- This case underscores the significant risk of drug-induced thrombocytopenia and subsequent hemorrhage with moxalactam disodium.
- Clinicians should be vigilant for hematological adverse effects when prescribing moxalactam, particularly in elderly or debilitated patients.